{"id":6619,"date":"2025-12-08T15:17:30","date_gmt":"2025-12-08T15:17:30","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&#038;p=6619"},"modified":"2026-02-02T18:13:06","modified_gmt":"2026-02-02T18:13:06","slug":"development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/","title":{"rendered":"Development of a High-Throughput Screening Platform for Kv2.2 Drug Discovery"},"content":{"rendered":"\n<h2 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-3-xl-font-size wp-elements-960d9dd8b39edb919b147fda9d1e332d\">Advancing Kv2.2 Drug Discovery<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Sygnature Discovery\u2019s ion channel screening platform provides reliable, high-quality data to support the search of novel starting points for Kv2.2 drug discovery. By integrating well-characterized cellular models with high-throughput fluorescence-based screening and automated electrophysiology, we offer a robust and scalable workflow designed to efficiently progress hit compounds through early-stage characterization.<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">With extensive expertise in ion channel pharmacology, we tailor each screening cascade to meet the specific needs to the project, ensuring both primary screening and follow-up electrophysiology profiling generate data that supports informed decision-making.<\/h3>\n\n\n\n<h3 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-25e4cdc2f8f9510344f929488ffd6d50\">Introduction<\/h3>\n\n\n\n<p>Voltage-gated potassium (Kv) channels are transmembrane proteins that mediate the selective passage of K+ ions across cellular membranes, playing critical roles in the regulation of neuronal excitability, cardiac excitability, muscle contraction and hormone secretion. The Kv channel family is categorized into twelve subfamilies \u2013 Kv1 to Kv12 \u2013 each consisting of multiple \u03b1-subunits that assemble into functional tetrameric channels. These channels exhibit distinct biophysical and pharmacological properties and play a critical role in modulating cellular excitability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-8704473d3f9ee0f7aadf68071c05c920\">Kv2.2 Therapeutic Potential<\/h2>\n\n\n\n<p>A recent study has identified a tumour-specific Kv2.2-associated ion channel complex uniquely expressed in GMB cells while absent in healthy brain tissue (Dong&nbsp;<em>et al.&nbsp;<\/em>2023). Therapeutic strategies employing synthetic peptides targeting this complex have demonstrated selective cytotoxicity against GMB cells and have significantly extended survival rate in preclinical models. These findings suggest that Kv2.2 may represent a promising molecular target for the development of novel, tumour selective therapies aimed at improving GMB treatment outcomes.<\/p>\n\n\n\n<p><em>Dong et al., Nature Cancer, 2023, PMID: 37697045<\/em><\/p>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-ivory-000-color has-text-color has-background is-layout-flow wp-block-group-is-layout-flow\" style=\"border-radius:1.5em;background:linear-gradient(90deg,rgb(0,60,97) 0%,rgb(4,30,46) 100%);margin-top:var(--wp--preset--spacing--40);margin-bottom:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--60);padding-left:var(--wp--preset--spacing--60)\" allowchildrentofillwidth=\"\" overflow=\"\" flexwrap=\"\">\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center has-small-font-size\" style=\"line-height:.9\"><strong>CASE STUDY<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\" id=\"schedule-a-visit\" style=\"font-size:clamp(20px, 1.25rem + ((1vw - 3.2px) * 0.938), 32px);line-height:1.15\"><strong>Download the PDF: Development of a High-Throughput Screening Platform for Kv2.2 Drug Discovery<\/strong><\/h2>\n\n\n\n<p class=\"has-text-align-center\">To read the full eBook please click the button below to download<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-50\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/Development-of-a-High-Throughput-Screening-Platform-for-Kv2.2-Drug-Discovery.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Download<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":0,"template":"","category":[707,708,746,780,687],"resource_tag":[],"class_list":["post-6619","case-study","type-case-study","status-publish","hentry","category-electrophysiology","category-high-throughput-screening","category-ion-channels","category-potassium-channels","category-target-classes"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kv2.2 Drug Discovery High-Throughput Screening Platform<\/title>\n<meta name=\"description\" content=\"Discovery Sygnature discovery&#039;s high-throughput Kv2.2 drug discovery screening platform, enabling profiling and lead optimization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kv2.2 Drug Discovery High-Throughput Screening Platform\" \/>\n<meta property=\"og:description\" content=\"Discovery Sygnature discovery&#039;s high-throughput Kv2.2 drug discovery screening platform, enabling profiling and lead optimization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T18:13:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\\\/\",\"name\":\"Kv2.2 Drug Discovery High-Throughput Screening Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"datePublished\":\"2025-12-08T15:17:30+00:00\",\"dateModified\":\"2026-02-02T18:13:06+00:00\",\"description\":\"Discovery Sygnature discovery's high-throughput Kv2.2 drug discovery screening platform, enabling profiling and lead optimization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Development of a High-Throughput Screening Platform for Kv2.2 Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kv2.2 Drug Discovery High-Throughput Screening Platform","description":"Discovery Sygnature discovery's high-throughput Kv2.2 drug discovery screening platform, enabling profiling and lead optimization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/","og_locale":"fr_CA","og_type":"article","og_title":"Kv2.2 Drug Discovery High-Throughput Screening Platform","og_description":"Discovery Sygnature discovery's high-throughput Kv2.2 drug discovery screening platform, enabling profiling and lead optimization.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/","og_site_name":"Sygnature","article_modified_time":"2026-02-02T18:13:06+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/","name":"Kv2.2 Drug Discovery High-Throughput Screening Platform","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"datePublished":"2025-12-08T15:17:30+00:00","dateModified":"2026-02-02T18:13:06+00:00","description":"Discovery Sygnature discovery's high-throughput Kv2.2 drug discovery screening platform, enabling profiling and lead optimization.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/development-of-a-high-throughput-screening-platform-for-kv2-2-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Development of a High-Throughput Screening Platform for Kv2.2 Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/6619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/case-study"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/6619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=6619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=6619"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=6619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}